Human Microbiome Market to Surpass US$ 306,351.2 Million by 2028 - Coherent Market Insights

Global Human Microbiome Market, by Product Type (Foods (Probiotics, Prebiotics, and Medical Foods), Fecal Microbiota Transplant (FMT), Microbiome Drugs, and Others), by Disease Indication (Clostridium Difficile Infection (CDI), Inflammatory Bowel Disease (IBD), Metabolic Disorders, Autoimmune Disorders, Allergic Diseases, and Others), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa), is estimated to be valued at US$ 91,075.4 million in 2021 and is expected to exhibit a CAGR of 18.9% during the forecast period (2021-2028).

Increase in venture financing and state funding for microbiome companies and research institutes is expected to accelerate microbiome drug development platform. This is expected to increase the growth of the global human microbiome market. Various investment firms and multinational pharmaceutical companies are financially supporting small biotech startup companies. In January 2018, Gnubiotics Sciences raised US$ 2.3 million through convertible debt with private investors and commercialized its first product candidate, GNU 100. The Valais-based biotech is developing a platform to commercialize microbiome modulating products for the functional and medical nutrition markets.

Market players are engaged in research and development activities, which is expected to increase the growth of the global human microbiome market. For instance, in September 2018, 4D Pharma plc., a pharmaceutical company leading the development of live biotherapeutics, announced positive top-line results for its Phase Ib study of Thetanix in paediatric patients with Crohn’s disease. The study achieved its primary objective, demonstrating that Thetanix was well-tolerated with a good safety profile.

Global Human Microbiome Market- Impact of Coronavirus (COVID – 19) Pandemic

The coronavirus disease (COVID-19) pandemic is expected to drive growth of the global human microbiome market over the forecast period. COVID-19 is the pandemic outbreak, which was first reported on December 31, 2019, in Wuhan, China. The World Health Organization declared coronavirus disease (COVID-19) as a pandemic on March 11, 2020. According to the Coronavirus Disease (COVID-19) Weekly Epidemiological Update by the World Health Organization, as on May 11, 2021, the number of new COVID-19 cases and deaths globally has slightly decreased the week, with over 5.5 million cases and over 90,000 deaths.

The COVID-19 pandemic has impacted the entire supply chain of the medical foods industry mainly due to strict lockdown in several regions. However, according to the article published in the International Journal of Microbiology: May 22, 2020, the use of probiotics is increasing during this COVID-19 pandemic times since coronavirus infection directly affects the human's immune system and the use of probiotics is expected to have positive effects on the immune responses.

According to the article published in Frontiers in Nutrition journal: December 15, 2020, probiotics interact with protein E of the SARS-CoV virus (protein E is associated with the growth of the SARS-CoV virus) and result in the internalization of the virion by stimulating macrophages, dendritic, and mast cells, thus stimulating the host immunity. Therefore, there is a huge demand for probiotics during COVID-19 pandemic.

 Browse 34 Market Data Tables and 28 Figures spread through 164 Pages and in-depth TOC on Global Human Microbiome Market, by Product Type (Foods, (Probiotics, Prebiotics, and Medical Foods), Fecal Microbiota Transplant (FMT), Microbiome Drugs, and Others), by Disease Indication (Clostridium Difficile Infection (CDI), Inflammatory Bowel Disease (IBD), Metabolic Disorders, Autoimmune Disorders, Allergic Diseases, and Others), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa).

To know the latest trends and insights prevalent in the human microbiome market, click the link below:

https://www.coherentmarketinsights.com/market-insight/human-microbiome-market-182

Increasing product launches by the market players is expected to increase the growth of the market over the forecast period. For instance, in November 2020, Beroni Group launched a new product ‘Beilemei’ in China. Beilemei is a probiotics health product aimed at modulating the balance of human intestinal flora. Moreover, in 2018, MicroBiome Therapeutics, LLC (MBT) launched first-in-class prebiotic dietary supplement named BiomeBliss. It is specifically developed to support a healthy gastrointestinal (GI) microbiome.

Key Takeaways of the Human Microbiome Market:

• The global human microbiome market is expected to exhibit a CAGR of 18.9% over the forecast period (2021-2028), owing to growth in potential markets, especially in Europe. North America accounted for major market share.
• Market players are indulged in inorganic activities such as collaboration with the research institutes for conducting the research and development for microbiome therapeutics. For instance, in 2017, Vedanta Biosciences entered into collaboration with Leiden University Medical Center and the University of South Alabama’s Mitchell Cancer Institute for cancer immunotherapy. The company also expanded its collaboration in cancer immunotherapy with NYU Langone Health and its Perlmutter Cancer Center. Through this collaboration, researchers analyzed microbiome clinical data from interventional checkpoint inhibitor studies to identify microbiome effects associated with response to immunotherapy and key mechanisms through which the gut microbiota affects immunotherapeutic responses.
• Some of the major players operating in the global human microbiome market include ENTEROME SA, Embion Technologies S.A, IGEN BIOLAB GROUP, Evelo Biosciences Inc., Ferring Pharmaceuticals, 4D Pharma Plc., Gnubiotics Sciences, YSOPIA Bioscience, ViThera Pharmaceuticals Inc., SECOND GENOME THERAPEUTICS, Osel Inc., OxThera AB, Immuron Ltd., AOBiome, Vedanta Biosciences, Inc., Rebiotix Inc., Seres Therapeutics, Inc., Assembly Biosciences, Inc., and Finch Therapeutics Group, Inc.